Brain protein may reveal who will regain weight after stopping popular weight loss drugs
NCT ID NCT06795360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 52 adults who are about to stop taking injectable weight loss drugs due to insurance changes. Researchers will measure a brain protein called Agouti-related peptide (AgRP) and track weight changes over 3 months. The goal is to see if this protein can predict who will regain weight after stopping the medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- discontinuation of weight loss medication
- What this could lead to
- If successful, this could help identify people at risk of regaining weight after stopping injectable weight loss drugs, allowing for better personalized care.
- What could go wrong
- This is a small observational study with only 52 participants, so results may not apply to everyone. It only looks at a 3-month period, so longer-term effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?